ArticleEuropean urology open science2025
Evaluation of Long-Term Outcomes Utilizing Indocyanine Green to Decrease Ureteroenteric Anastomotic Stricture During Robotic Radical Cystectomy and Extracorporeal Urinary Diversion.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eye-hand coordination during robotic prostate cancer surgery - how surgical vision reflects on instrument kinematics and vice versa.Journal of robotic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Intravenous indocyanine green (ICG) allows assessment of ureteral perfusion when performing ureteroenteric anastomosis. Our aim was to evaluate the impact of ICG use and clinical factors on the risk of ureteroenteric anastomotic stricture (UAS) following robot-assisted radical cystectomy (RARC) and extracorporeal urinary diversion (ECUD). Methods: We conducted a retrospective review of patients who underwent RARC + ECUD with or without ICG use between 2011 and 2022 at a single tertiary center. For cases with a clinical suspicion of UAS, a nephrostomy tube was placed and an antegrade nephrostogram was performed for confirmation. Kaplan-Meier and logistic regression analyses were performed to estimate stricture rates and to identify risk factors for UAS incidence. Results and limitations: A total of 392 consecutive cases were included. No ICG was used for the first 196 cases (50%), while ICG was used for the subsequent 196 cases (50%). ECUDs included 234 ileal conduits (60%), 110 neobladders (28%), and 48 Indiana pouches (12%). The risk of UAS was 2% at 6-months and 3% at 24-months in the ICG group, and 12% at 6-months and 14% at 24-months in the non-ICG group. No UAS occurred beyond 19-months. Multivariable analysis revealed that ICG use significantly reduced UAS risk (hazard ratio [HR] 0.20, 95% confidence interval [CI] 0.08-0.50; Conclusions and clinical implications: ICG fluorescence imaging is a safe technique that can facilitate efforts to reduce the risk of UAS following RARC and ECUD. Patient summary: Narrowing of the connection between the ureter and the segment of intestine used to create a new urinary reservoir is a serious complication after bladder removal for bladder cancer. We found that using a fluoroscent agent that identifies tissue blood supply at the time of urinary reconstruction may reduce the risk of this complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.